Results

Most recent

AMD-Neovascular

1–10 of 166 results for AMD-Neovascular

Ixoberogene Soroparvovec (Ixo-vec) IVT Gene Therapy for Neovascular AMD: Phase 2 LUNA Study Update
Glenn C. Yiu, MD, PhD
Updates from the Field
2025
Prophylactic Intraocular Pressure–Lowering Measures in Antivascular Endothelial Growth Factor Therapy: Systematic Review and Meta-Analysis
Parnian Arjmand, MD, MSc, FRCSC, DABO
Annual Meeting Talks
2022
Baseline Factors Associated With 1-Year Outcomes in Phase III Comparison of SB11 (Approved Ranibizumab Biosimilar) With Reference Ranibizumab in nAMD
Neil M. Bressler, MD
Annual Meeting Talks
2022
Ixoberogene Soroparvovec (Ixo-vec) IVT Gene Therapy for Neovascular AMD: First Time 26-Week Interim Analysis Results from the Phase 2 LUNA Study
Charles C Wykoff, MD, PhD, FASRS
Updates from the Field
2024
Analysis of the Long-term Visual Outcomes of ForeseeHome Remote Telemonitoring.
Michael J. Elman, MD
Annual Meeting Talks
2022
Subretinal Pneumatic Displacement Without Tissue Plasminogen Activator for Submacular Hemorrhage: One-year Outcomes
Marwan Abdulaal, MD
Annual Meeting Talks
2022
Higher Order OCT Feature Assessment of the Impact of Fluid Dynamics on Visual Acuity in Neovascular AMD in a Phase III Clinical Trial: The Importance of Outer Retinal Integrity
Justis P. Ehlers, MD, FASRS
Annual Meeting Talks
2022
ADVM-022 Intravitreal Gene Therapy for Neovascular AMD: Phase 1 OPTIC Trial Update
Dante Joseph Pieramici, MD
Annual Meeting Talks
2022
Conversion Rates from Nonexudative to Exudative Age-Related Macular Degeneration: An AAO IRIS® Registry Analysis
Dan A Gong, MD
Annual Meeting Talks
2022
Phase IIIb TALON study of brolucizumab versus aflibercept in a matched treat-and-extend regimen to treat neovascular AMD: 32-week primary outcomes
Carl D. Regillo, MD
Annual Meeting Talks
2022